Pharvaris (NASDAQ:PHVS) President Peng Lu Sells 100,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 100,000 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the transaction, the president owned 64,953 shares in the company, valued at approximately $2,273,355. The trade was a 60.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Peng Lu also recently made the following trade(s):

• On Friday, September 11th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $40.13, for a total transaction of $601,950.00.
• On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $40.68, for a total transaction of $610,200.00.

Pharvaris Trading Down 1.0%

Shares of PHVS traded down $0.35 during mid-day trading on Monday, hitting $36.02. The company’s stock had a trading volume of 653,689 shares, compared to its average volume of 412,750. The company’s 50-day moving average is $35.37 and its 200-day moving average is $31.75. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of -11.81 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PHVS shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Pharvaris in a report on Monday, September 14th. Guggenheim raised their price objective on Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Royal Bank Of Canada lifted their target price on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. HSBC upgraded shares of Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Finally, Citizens Jmp raised their price target on shares of Pharvaris from $75.00 to $79.00 and gave the company a “market outperform” rating in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $59.87.

Institutional Trading of Pharvaris

Several hedge funds and other institutional investors have recently made changes to their positions in PHVS. venBio Partners LLC acquired a new stake in shares of Pharvaris in the 2nd quarter worth $160,569,809. Wellington Management Group LLP increased its position in Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares in the last quarter. Commodore Capital LP increased its position in Pharvaris by 1.6% during the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after buying an additional 29,525 shares in the last quarter. 5AM Venture Management LLC purchased a new stake in Pharvaris in the second quarter valued at about $27,581,008. Finally, Seven Fleet Capital Management LP raised its stake in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after buying an additional 457,804 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.